Sugi Predict
/ Targets
/ POLM
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to POLM by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection |
PHASE3 | UNKNOWN |
| Intracameral Antibiotic Safety Study |
PHASE3 | SUSPENDED |
| Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) |
PHASE3 | COMPLETED |
| Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer |
PHASE2 | UNKNOWN |
| Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma |
PHASE1/PHASE2 | COMPLETED |
| Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs |
PHASE2 | COMPLETED |
| Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Endometrial Receptivity in Patients With Recurrent Implantation Failure as a Preparatory Step for PET |
PHASE1/PHASE2 | UNKNOWN |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors |
PHASE1 | COMPLETED |
| Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers |
PHASE1 | COMPLETED |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers |
PHASE1 | COMPLETED |
| GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia |
PHASE1 | COMPLETED |
| An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer |
nan | NOT_YET_RECRUITING |
| Choroid Plexus Dysfunction in Neurological Diseases |
nan | RECRUITING |
| Spironolactone and XPB-1 Integrity in the TFIIH Complex |
nan | ENROLLING_BY_INVITATION |
| DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease |
nan | COMPLETED |
| Cohort of Tumors With POLE/D1 Mutation |
nan | RECRUITING |
| Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer |
nan | UNKNOWN |
| Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission. |
nan | UNKNOWN |
| Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation |
nan | UNKNOWN |
| Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome) |
nan | COMPLETED |
| Primary and Secondary Drug Resistance Mutations (DRMs) in HIV As a Risk Factor of Failure of ART, Including Two Drugs Based Regimens. |
nan | NOT_YET_RECRUITING |
| A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a POLM binder may also engage these)